Oxford, UK - 10 March 2008: Oxford BioMedica (LSE: OXB), a leading gene therapy company, announced today that Dr Alexander D Lewis will join the Board on 3 April 2008 as a Non-executive Director and member of the Remuneration and Audit Committees.

Dr Lewis is an experienced consultant to the pharmaceutical and biotech industry with a background of over 20 years in medical research and drug development. Until 1 January 2008, Dr Lewis was head of the Partnering and Due Diligence Practice at leading consultants Wood Mackenzie and was based in their Boston office. Dr Lewis’ assignments have involved supporting investment banks with their corporate finance activities, including selection of acquisition targets, due diligence, expert reports and listing particulars; as well as advising pharmaceutical and biotech clients with their licensing strategy for in and out licensing and asset identification, general corporate strategy in terms of research and development and also mergers and acquisitions; and also performing due diligence on companies, products and technologies. Dr Lewis has also been involved in the provision of the expert reports and technical advice for Initial Public Offerings (IPO’s) and fundraising activities of biotech companies based in the USA and Europe.

Professor Alan Kingsman, Chief Executive Officer of Oxford BioMedica, said: "We are delighted that Alex has agreed to join the board of Oxford BioMedica. His exceptional experience and broad-based knowledge will complement the existing team and help take the Company forward through its next exciting stages of commercial and operational development."

There is no other information to be disclosed under Paragraph 9.6.13 R of the Listing Rules.

-Ends-

For further information, please contact:

Oxford BioMedica plc:
Professor Alan Kingsman, Chief Executive
Tel: +44 (0)1865 783 000

JPMorgan Cazenove Limited:
James Mitford/ Gina Gibson
Tel: +44 (0)20 7588 2828

City/Financial Enquiries:
Lisa Baderoon/ Mark Court/ Mary-Jane Johnson Buchanan Communications
Tel: +44 (0)20 7466 5000

Scientific/Trade Press Enquiries:
Gemma Price/ Holly Griffiths/ Katja Stout
College Hill Life Sciences
Tel: +44 (0)20 7457 2020

US Enquiries:
Thomas Fechtner
The Trout Group LLC
Tel: (646) 378 2900

Notes to editors

1. Oxford BioMedica

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in cancer immunotherapy and gene-based therapies. The Company was established in 1995, as a spin-out from Oxford University, and is listed on the London Stock Exchange.

The Company has a platform of gene delivery technologies, which are based on highly engineered viral systems. Oxford BioMedica also has in-house clinical, regulatory and manufacturing know-how. The lead product candidate is TroVax®, an immunotherapy for multiple solid cancers, which is licensed to sanofi-aventis for global development and commercialisation. TroVax is in Phase III development. Oxford BioMedica has three other products in clinical development, including ProSavin®, a novel gene-based treatment for Parkinson’s disease, in a Phase I/II trial. The Company is underpinned by over 80 patent families, which represent one of the broadest patent estates in the field. The Company has a staff of approximately 85. Oxford BioMedica has collaborations with sanofi-aventis, Wyeth, Sigma-Aldrich, MolMed and Virxsys. Technology licensees include Biogen Idec, Merck & Co, GlaxoSmithKline and Pfizer.

Further information is available at www.oxfordbiomedica.co.uk